Nature research shows mitochondrial metabolism drives heart aging

Mitochondrial Protein Loss Triggers Heart Decline

Published in the journal Circulation, the research shows that STMP1 levels drop significantly with age and in patients suffering from dilated cardiomyopathy.

When cardiomyocytes lack sufficient STMP1, damaged mitochondrial folds cause mitochondrial DNA to leak into the cell cytoplasm. The cell mistakenly perceives this internal leak as an external infection, activating the cGAS–STING immune alert pathway. Led by first author Francesco Paolo Ruberto and corresponding author Roger Foo, the team observed that this process drives persistent inflammation, energy disruption, cell death, and cardiac fibrosis leading to heart failure.

Preclinical Interventions Reverse Cardiac Decline in Models

The Singapore research team tested two distinct intervention strategies in laboratory models to combat this cascade. Restoring heart STMP1 concentrations via a gene delivery system successfully improved mitochondrial structure, lowered inflammation, and restored heart contraction function.

Early administration of drugs to block the STING pathway also reduced inflammation and heart fibrosis. However, the researchers noted that treatment failed to reverse functional decline if administered after mitochondria had already sustained severe damage. These findings indicate that inflammatory signals emerge before overt signs of heart failure appear.

Metabolic Shifts Rewrite Epigenetics in Aging Cells

A separate international collaboration led by Peter Adams of the Sanford Burnham Prebys Medical Research Institute and João Passos of Mayo Clinic published findings in Nature detailing how senescent, or zombie, cells alter gene regulation. Their work demonstrates that mitochondrial metabolism in aging cells produces excess acetyl-CoA, which modifies histone proteins and loosens DNA packaging.

This structural change makes senescence-associated secretory phenotype (SASP) inflammatory genes much easier to transcribe. Combined with immune signals triggered by leaked mitochondrial DNA and RNA, these two parallel pathways converge to sustain long-term chronic inflammation that accelerates tissue aging.

Targeting Metabolic Signals Extends Health Span

To test potential therapies against this metabolic pathway, the team used the selective inhibitor drug CTPI-2 to block the transporter protein required to synthesize acetyl-CoA. Experiments in older mice showed that restricting this metabolic signal and reducing inflammatory gene accessibility successfully suppressed inflammation across multiple organs, improved organ function, and extended healthy lifespan, even though leaked mitochondrial immune signals remained present.

All current intervention methods, including gene delivery, STING inhibitors, and CTPI-2, remain strictly within the preclinical testing stage in cells and mouse models. Future research plans include evaluating safety and efficacy in larger animal models that closely mimic human disease characteristics, alongside investigating STMP1 as an early diagnostic biomarker for potential clinical translation.